Azurity Pharmaceuticals Acquires Covis Pharma

Covis Group Acquires AMAG Pharmaceuticals

November 16, 2020

Pharmaceuticals

Covis Group S.à r.l. completed a cash tender offer and merger to acquire AMAG Pharmaceuticals, Inc. for $13.75 per share, taking AMAG private and delisting its NASDAQ shares. The acquisition adds AMAG’s marketed products (including Feraheme and Makena) and development-stage assets in women’s health and hematology/oncology to Covis’ specialty pharma portfolio, supported by financing from Capital One and investment funds managed by HPS Investment Partners.

Azurity Pharmaceuticals to Acquire and Merge with Arbor Pharmaceuticals

September 24, 2021

Pharmaceuticals

Azurity Pharmaceuticals, majority-owned by NovaQuest Private Equity, has entered into a definitive agreement to acquire Arbor Pharmaceuticals from existing investors including JW Asset Management and KKR. The companies will merge and operate as Azurity, creating a larger specialty pharmaceuticals business with an expanded portfolio across neuroscience, cardiovascular, GI, endocrinology and institutional markets; the transaction is expected to close pending regulatory approvals.

AmerisourceBergen Acquires PharmaLex from AUCTUS in €1.28bn Transaction

December 31, 2022

Healthcare Services

AmerisourceBergen Corporation acquired a majority stake in PharmaLex from funds advised by AUCTUS Capital Partners AG in a transaction that closed at year-end 2022 for approximately EUR 1.28 billion. PharmaLex, a Germany-headquartered provider of regulatory, clinical development and pharmacovigilance services to the life sciences industry, was grown under AUCTUS through a buy-and-build program of 38 add-ons and will expand AmerisourceBergen's global pharmaceutical solutions.

Covis Acquires Global Rights to Eklira and Duaklir from AstraZeneca

January 5, 2022

Pharmaceuticals

Covis Pharma Group completed the acquisition of global rights to the respiratory medicines Eklira (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol) from AstraZeneca for an upfront payment of $270 million, with additional payments tied to ongoing development costs. Covis also entered an exclusive promotion and distribution agreement with Novartis Pharmaceuticals Canada to distribute Seebri Breezhaler and Ultibro Breezhaler in Canada, strengthening Covis' respiratory platform and market position.

ATHAGORAS Group Acquires CSO Pharma Consulting GmbH

November 18, 2024

Healthcare Services

ATHAGORAS Group has acquired CSO Pharma Consulting GmbH to expand and internationalize its pharmacovigilance, medical affairs, quality management and GDP consulting capabilities across the pharma and healthcare sectors. The deal adds a specialized provider of PV and regulatory support to ATHAGORAS' life‑sciences services platform while CSO retains focus on organic growth and continuity for clients and employees.

Azurity Pharmaceuticals Acquires Slayback Pharma

September 27, 2023

Pharmaceuticals

Azurity Pharmaceuticals has completed the acquisition of Slayback Pharma LLC from existing investors including KKR and Everstone Capital, making Slayback a wholly owned subsidiary of Azurity. The deal expands Azurity's R&D and complex formulation capabilities and accelerates its pipeline for new medicine launches as part of its growth strategy under majority owner QHP Capital.